Nuance matters in clinical practice. The 2026 Dyslipidemia Guidelines

The newly released 2026 ACC/AHA Dyslipidemia Guideline represents a massive collaborative effort across eleven co-signing societies, introducing critical updates like new LDL targets and universal Lp(a) screening. It is a vital playbook for primary care.However, implementing these updates effectively requires us to look closely at how recommendations are categorized.As clinicians, it is easy to look at a Class of Recommendation 1 (COR 1) and treat it as a mandate backed by definitive randomized controlled trial (RCT) evidence. But the guidelines themselves are transparent that COR 1 can also be applied to areas guided primarily by expert consensus (LOE C-EO) or limited data (LOE C-LD) when trials aren't feasible.In my latest episode, I break down why understanding this distinction is essential for tailored patient care.The Methodology: The structural difference between COR 1 backed by RCTs versus expert opinion.The Primary Care Lens: How to translate specialized guideline frameworks into daily, real-world primary care practice.A truly comprehensive critical appraisal means understanding both the strength of a recommendation and the nature of the data supporting it.Discussion for the community: How do you balance strong guideline recommendations with expert-consensus levels of evidence when discussing treatment plans with your patients?#InternalMedicine #PrimaryCare #Cardiology #EvidenceBasedMedicine #MedEd #Dyslipidemia2026 #familymedicine #dispenseaswritten